L3VLUP
ProSign in

RVMD · GILD in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

RVMDGILD
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • RVMD
  • GILD
010203040202120222023202420252026
Holders and value by quarter
QuarterRVMDGILD
Q3 20203 holders, $388m25 holders, $14.2bn
Q4 20204 holders, $451m27 holders, $13.4bn
Q1 20215 holders, $846m24 holders, $14.5bn
Q2 20215 holders, $325m18 holders, $14.9bn
Q3 20213 holders, $133m20 holders, $16.4bn
Q4 20213 holders, $174m20 holders, $16.8bn
Q1 20223 holders, $174m28 holders, $13.2bn
Q2 20223 holders, $189m26 holders, $13.6bn
Q3 20223 holders, $206m24 holders, $13.3bn
Q4 20223 holders, $263m32 holders, $21.1bn
Q1 20235 holders, $526m27 holders, $21.8bn
Q2 20237 holders, $685m24 holders, $20.7bn
Q3 20238 holders, $766m24 holders, $20.0bn
Q4 20238 holders, $1.0bn22 holders, $21.5bn
Q1 202410 holders, $1.3bn30 holders, $20.3bn
Q2 20249 holders, $1.6bn28 holders, $18.5bn
Q3 202410 holders, $1.9bn29 holders, $24.2bn
Q4 202411 holders, $2.2bn28 holders, $25.9bn
Q1 20257 holders, $1.7bn33 holders, $32.0bn
Q2 20258 holders, $1.7bn27 holders, $30.9bn
Q3 20257 holders, $2.2bn23 holders, $29.4bn
Q4 202518 holders, $4.3bn25 holders, $34.3bn
Q1 202615 holders, $4.8bn25 holders, $38.5bn
Q2 202617 holders, $10.3bn26 holders, $34.2bn
RVMD

Revolution Medicines Inc

Holders
17
Reported value
$10.3bn
Buyers
16
Sellers
23

Breadth -7 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP
GILD

Gilead Sciences Inc

Holders
26
Reported value
$34.2bn
Buyers
22
Sellers
16

Breadth +6 among 91 comparable managers.

Pharmaceuticals and biotechnologyBiological productsHealthcare: biopharma and medtech · L3VLUP

Who holds both, Q2 2026

Among the 34 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only RVMD (8)

AQR Capital Management LLC, Baillie Gifford & Co, ExodusPoint Capital Management LP, Farallon Capital Management LLC, Freestone Grove Partners LP, Marshall Wace LLP, Moore Capital Management LP, Two Sigma Investments LP

Only GILD (17)

AllianceBernstein LP, Arrowstreet Capital LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Citadel Advisors LLC, D. E. Shaw & Co., Dodge & Cox, Invesco Ltd, Millennium Management LLC, Neuberger Berman Group LLC, Point72 Asset Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, Squarepoint Ops LLC, Voloridge Investment Management LLC

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →